Xin-Long Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xin-Long Ma has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Guixing Qiu
Department of Orthopedics, Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China
1 shared publication Jian-Xiong Ma
Tianjin Hosptial
1 shared publication- Liang Chen
Suzhou University, Affiliated Hospital 1, Department of Orthopaedic, Suzhou, China
1 shared publication - Ming-Jie Kuang
Department of Orthopedics Shandong Provincial Hospital Affiliated with Shandong First Medical University Jinan Shandong China
1 shared publication - Qiang Yang
Department of Spine Surgery, Tianjin Hospital, Tianjin University, Tianjin, China
1 shared publication - Sheng Lu
Department of Orthopedics, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China
1 shared publication
Latest Publications
- Open Access
- 20 January 2025
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 50, 364-372
Guideline for adolescent scoliosis screening in China (public version 2024)
- 20 January 2025
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 50, 364-372
Open AccessGuideline for adolescent scoliosis screening in China (public version 2024)
- Open Access
- 27 August 2019
- Published by Springer Nature in Research Square
Is Romosozumab better than Teriparatide for the treatment of osteoporosis? A meta-analysis through a grade analysis of evidence
Background Osteoporosis is a common systemic skeletal disease. With an ageing population, the socioeconomic effect of osteoporosis will remarkably improve. Romosozumab (EVENITYTM) is a new osteoanabolic drug, which is a humanised monoclonal antibody against sclerostin, and received its first global approval for the treatment of osteoporosis in patients at high risk of fracture in Japan on January 8, 2019. Teriparatide is the first osteoanabolic drug. However, there is no comprehensive analysis and systematic review about the efficacy and safety of the two treatment. Method Randomized controlled trials (RCTs) about our analysis were searched from electronic database, including Pubmed (1996 to June 2019), Embase (1980 to June 2019), Cochrane Library (CENTRAL, June 2019), Web of Science (1998 to June 2019) and others. Four studies were included in our meta-analysis. Results Four studies containing 1304 patients meet our selection criteria. Our result of analysis indicated that Romosozumab showed better effects in improving BMD of lumbar spine (month 6: MD=3.54, 95% CI [3.13, 3.94], P<0.00001; month 12: MD=4.93, 95% CI [4.21, 5.64], P<0.00001), total hip (month 6: MD=2.27, 95% CI [0.62, 3.91], P=0.007; month 12: MD=3.17, 95% CI [2.68, 3.65], P<0.00001) and femoral neck (month 6: MD=2.30, 95% CI [0.51, 4.08], P=0.01; month 12: MD=3.04, 95% CI [2.29, 3.78], P<0.00001). And the injection-site reaction was fewer (month 12: RR=2.84, 95% CI [1.22, 6.59], P=0.02).But there were no significant differences in the incidence of serious adverse events (month 12: RR=0.78, 95% CI [0.46, 1.33], P=0.37), and death (month 12: RR=0.61, 95% CI [0.08, 4.62], P=0.63). Conclusion Based on the available studies, our current results demonstrated that Romosozumab was better than Teriparatide both in terms of efficacy and side effects.
- 27 August 2019
- Published by Springer Nature in Research Square
Open AccessIs Romosozumab better than Teriparatide for the treatment of osteoporosis? A meta-analysis through a grade analysis of evidence
Background Osteoporosis is a common systemic skeletal disease. With an ageing population, the socioeconomic effect of osteoporosis will remarkably improve. Romosozumab (EVENITYTM) is a new osteoanabolic drug, which is a humanised monoclonal antibody against sclerostin, and received its first global approval for the treatment of osteoporosis in patients at high risk of fracture in Japan on January 8, 2019. Teriparatide is the first osteoanabolic drug. However, there is no comprehensive analysis and systematic review about the efficacy and safety of the two treatment. Method Randomized controlled trials (RCTs) about our analysis were searched from electronic database, including Pubmed (1996 to June 2019), Embase (1980 to June 2019), Cochrane Library (CENTRAL, June 2019), Web of Science (1998 to June 2019) and others. Four studies were included in our meta-analysis. Results Four studies containing 1304 patients meet our selection criteria. Our result of analysis indicated that Romosozumab showed better effects in improving BMD of lumbar spine (month 6: MD=3.54, 95% CI [3.13, 3.94], P<0.00001; month 12: MD=4.93, 95% CI [4.21, 5.64], P<0.00001), total hip (month 6: MD=2.27, 95% CI [0.62, 3.91], P=0.007; month 12: MD=3.17, 95% CI [2.68, 3.65], P<0.00001) and femoral neck (month 6: MD=2.30, 95% CI [0.51, 4.08], P=0.01; month 12: MD=3.04, 95% CI [2.29, 3.78], P<0.00001). And the injection-site reaction was fewer (month 12: RR=2.84, 95% CI [1.22, 6.59], P=0.02).But there were no significant differences in the incidence of serious adverse events (month 12: RR=0.78, 95% CI [0.46, 1.33], P=0.37), and death (month 12: RR=0.61, 95% CI [0.08, 4.62], P=0.63). Conclusion Based on the available studies, our current results demonstrated that Romosozumab was better than Teriparatide both in terms of efficacy and side effects.